All subjects who met the official clinicopathological criteria for AD [ADNPC, defined as the presence of Abeta plaques, neurofibrillary tangles, and neuritic plaques (Montine et al., 2012)] in standard microscopy also showed Abeta and Tau in immunohistochemistry (Robinson et al., 2018b). The gene discussed is MAPT; the disease is Alzheimer disease.